Melittin exerts an antitumor effect on non‑small cell lung cancer cells

Zhang,Su‑Fang; Chen,Zhe

doi:10.3892/mmr.2017.6970

Melittin exerts an antitumor effect on non‑small cell lung cancer cells

Authors:
- Su‑Fang Zhang
- Zhe Chen
View Affiliations

Affiliations: Department of Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital of Tongji University School of Medicine, Shanghai 200433, P.R. China, Department of Traditional Chinese Medicine, Changhai Hospital of Second Military Medical University, Shanghai 200433, P.R. China
Published online on: July 14, 2017 https://doi.org/10.3892/mmr.2017.6970
Pages: 3581-3586

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer accounts for a significant percentage of all cancer‑associated mortalities in men and women, with non‑small cell lung cancer being the most frequently occurring type of lung cancer. Melittin is the principal active component of apitoxin (bee venom) that has been reported to exert anti‑chronic inflammatory and anti‑cancer effects. In the present study, the antitumor effect of melittin was evaluated using in vivo and in vitro analyses. The results demonstrated that melittin significantly inhibited the epidermal growth factor‑induced invasion and migration of non‑small cell lung cancer cells. Subcutaneous injection of melittin at doses of 1 and 10 mg/kg significantly suppressed non‑small cell lung cancer tumor growth by 27 and 61%, respectively. In addition, melittin significantly inhibited the secretion of vascular endothelial growth factor (VEGF) in non‑small cell lung cancer cells. Furthermore, melittin decreased the protein expression of VEGF and hypoxia‑inducible factor 1‑α. Therefore, the antitumor activity of melittin may be associated with the anti‑angiogenic actions of inhibiting the VEGF and hypoxia‑inducible factor signaling pathways.

View Figures

View References

1	Atlanta: Cancer Facts & Figures 2015. American Cancer Society; 2015:
2	Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M, McAfee TA, et al: Centers for Disease Control and Prevention (CDC): Lung cancer incidence trends among men and women-United States, 2005–2009. MMWR Morb Mortal Wkly Rep. 63:1–5. 2014.PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Liam CK, Andarini S, Lee P, Ho JC, Chau NQ and Tscheikuna J: Lung cancer staging now and in the future. Respirology. 20:526–34. 2015. View Article : Google Scholar : PubMed/NCBI
5	Tsao AS and Papadimitrakopoulou V: The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: Focus on clinical trial results. Clin Lung Cancer. 14:311–321. 2013. View Article : Google Scholar : PubMed/NCBI
6	Heinen TE and da Veiga AB: Arthropod venoms and cancer. Toxicon. 57:497–511. 2011. View Article : Google Scholar : PubMed/NCBI
7	Song HS, Ko MS, Jo YS, Whang WK and Sim SS: Inhibitory effect of acteoside on melittin-induced catecholamine exocytosis through inhibition of Ca(2+)-dependent phospholipase A2 and extracellular Ca(2+) influx in PC12 cells. Arch Pharm Res. 38:1913–1920. 2015. View Article : Google Scholar : PubMed/NCBI
8	Mulder KC, Lima LA, Miranda VJ, Dias SC and Franco OL: Current scenario of peptide-based drugs: The key roles of cationic antitumor and antiviral peptides. Front Microbiol. 4:3212013. View Article : Google Scholar : PubMed/NCBI
9	Liu S, Yu M, He Y, Xiao L, Wang F, Song C, Sun S, Ling C and Xu Z: Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 47:1964–1973. 2008. View Article : Google Scholar : PubMed/NCBI
10	Raghuraman H and Chattopadhyay A: Melittin: A membrane-active peptide with diverse functions. Biosci Rep. 27:189–223. 2007. View Article : Google Scholar : PubMed/NCBI
11	Orsolic N: Bee venom in cancer therapy. Cancer Metastasis Rev. 31:173–194. 2012. View Article : Google Scholar : PubMed/NCBI
12	Jeong YJ, Choi Y, Shin JM, Cho HJ, Kang JH, Park KK, Choe JY, Bae YS, Han SM, Kim CH, et al: Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells. Food Chem Toxicol. 68:218–225. 2014. View Article : Google Scholar : PubMed/NCBI
13	Shin JM, Jeong YJ, Cho HJ, Park KK, Chung IK, Lee IK, Kwak JY, Chang HW, Kim CH, Moon SK, et al: Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One. 8:e693802013. View Article : Google Scholar : PubMed/NCBI
14	Choi JY, Hong WG, Cho JH, Kim EM, Kim J, Jung CH, Hwang SG, Um HD and Park JK: Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death via cell cycle arrest, ER stress and autophagy. Int J Oncol. 47:1257–1265. 2015.PubMed/NCBI
15	Yang X, Zhu H, Ge Y, Liu J, Cai J, Qin Q, Zhan L, Zhang C, Xu L, Liu Z, et al: Melittin enhances radiosensitivity of hypoxic head and neck squamous cell carcinoma by suppressing HIF-1α. Tumour Biol. 35:10443–10448. 2014. View Article : Google Scholar : PubMed/NCBI
16	Samarajeewa NU, Yang F, Docanto MM, Sakurai M, McNamara KM, Sasano H, Fox SB, Simpson ER and Brown KA: HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Res. 15:R302013. View Article : Google Scholar : PubMed/NCBI
17	Schnabel PA and Junker K: Neuroendocrine tumors of the lungs. From small cell lung carcinoma to diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Pathologe. 35:557–564. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mahmood S, Bilal H, Faivre-Finn C and Shah R: Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer? Interact Cardiovasc Thorac Surg. 17:845–853. 2013. View Article : Google Scholar : PubMed/NCBI
19	Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, Stubbs RW, Bertozzi-Villa A, Morozoff C, Charara R, Allen C, Naghavi M and Murray CJ: Trends and patterns of disparities in cancer mortality among US counties, 1980–2014. JAMA. 317:388–406. 2017. View Article : Google Scholar : PubMed/NCBI
20	Spira A, Halmos B and Powell CA: Update in lung cancer 2014. Am J Respir Crit Care Med. 192:283–294. 2015. View Article : Google Scholar : PubMed/NCBI
21	Gajski G and Garaj-Vrhovac V: Melittin: A lytic peptide with anticancer properties. Environ Toxicol Pharmacol. 36:697–705. 2013. View Article : Google Scholar : PubMed/NCBI
22	Gerst JE and Salomon Y: Inhibition by melittin and fluphenazine of melanotropin receptor function and adenylate cyclase in M2R melanoma cell membranes. Endocrinology. 121:1766–1772. 1987. View Article : Google Scholar : PubMed/NCBI
23	Duke RC, Witter RZ, Nash PB, Young JD and Ojcius DM: Cytolysis mediated by ionophores and pore-forming agents: Role of intracellular calcium in apoptosis. FASEB J. 8:237–246. 1994.PubMed/NCBI
24	Prager GW, Poettler M, Unseld M and Zielinski CC: Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res. 1:14–25. 2012.PubMed/NCBI
25	Holle L, Song W, Holle E, Wei Y, Wagner T and Yu X: A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol. 22:93–98. 2003.PubMed/NCBI
26	Moon DO, Park SY, Heo MS, Kim KC, Park C, Ko WS, Choi YH and Kim GY: Key regulators in bee venom-induced apoptosis are Bcl-2 and caspase-3 in human leukemic U937 cells through downregulation of ERK and Akt. Int Immunopharmacol. 6:1796–1807. 2006. View Article : Google Scholar : PubMed/NCBI